No coercive steps to be taken against drug firms for FDCs already in market: Delhi HC

No coercive steps are taken against FDC drug Indian pharma major Wockhardt for sale of stock, already in the market, of its anti-inflammatory medicine which has been banned, subject to the company stopping further production of the drug.

New Delhi: The Delhi High Court said that no coercive steps be taken against drug companies for FDCs already in the market, subject to stopping of their manufacturing.

Justice Vibhu Bakhru granted the relief to some drug manufacturers after they approached the high court.

It had said earlier that no coercive steps be taken against Indian pharma major Wockhardt for sale of stock, already in the market, of its anti-inflammatory medicine which has been banned, subject to the company stopping further production of the drug.

Read Also: Ace Proxyvon Banned: Wockhardt moves Court against a ban on Aceclofenac, Paracetamol, Rabeprazole Combo

The court, in an interim order, had said the medicine, one of 328 fixed-dose combinations (FDC) drugs banned by the Centre a week ago, has been in the market for past 11 years and its stocks would already be in the distribution network.

Read also: 328 FDC Medicines banned over safety concern: Health Ministry Notification

The board had recommended that it was necessary to prohibit the manufacture, sale or distribution of these FDCs under the Drugs and Cosmetics Act, 1940 in larger public interest.

Read Also: Health Ministry bans 328 FDC Banned Drugs, check out the complete list